Valuation: PTC Therapeutics, Inc.

Market Cap 531.23Cr 471.87Cr 441.98Cr 400.25Cr 754.83Cr 51TCr 760.93Cr 5.3TCr 2.06TCr 26TCr 1.99TCr 1.95TCr 84TCr P/E 2026 *
41.3x
P/E 2027 * 24.9x
Enterprise Value 344.12Cr 305.66Cr 286.31Cr 259.27Cr 488.96Cr 33TCr 492.91Cr 3.44TCr 1.34TCr 17TCr 1.29TCr 1.26TCr 54TCr EV / Sales 2026 *
2.74x
EV / Sales 2027 * 2.3x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -
1 day+0.08%
1 week-3.41%
Current month-1.67%
1 month-8.08%
3 months-23.54%
6 months-6.01%
Current year-16.14%
1 week 62.6
Extreme 62.6
65.56
1 month 61.23
Extreme 61.23
70.08
Current year 61.23
Extreme 61.23
90.87
1 year 61.23
Extreme 61.23
90.87
3 years 17.53
Extreme 17.53
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 4.03
Extreme 4.03
90.87
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2023
Director of Finance/CFO 41 13/07/2023
Chief Tech/Sci/R&D Officer - 01/10/2017
Director TitleAgeSince
Chairman 74 01/11/2004
Chairman 80 31/03/1998
Director/Board Member 65 01/12/2005
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Exercice

Director

36,000 0.0431%
17/09/26
Section Six Partners
SellCompany -10,000 0.0120%
16/09/26 Other

Chairman

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+0.08%-3.41%-2.55%+186.94% 531.23Cr
+1.26%-2.30%+37.82%+113.76% 1,01900Cr
+0.73%-6.31%+35.06%+62.14% 61TCr
+0.35%+0.15%+14.01%+80.87% 47TCr
+1.72%-4.54%+59.14%+37.01% 34TCr
+0.26%-1.58%+21.97%+41.79% 34TCr
+0.60%-3.48%+11.37%+34.33% 27TCr
+1.65%-4.27%-5.47%+9.69% 24TCr
-0.09%-3.71%+35.15%+51.88% 22TCr
-0.28%-5.24%+27.99%+93.08% 18TCr
Average +0.37%-3.61%+23.45%+71.15% 36.88TCr
Weighted average by Cap. +0.32%-3.51%+29.44%+70.23%

Financials

2026 *2027 *
Net sales 125.78Cr 111.73Cr 104.65Cr 95Cr 178.72Cr 12TCr 180.17Cr 1.26TCr 488.38Cr 6.18TCr 472.11Cr 461.97Cr 20TCr 137.69Cr 122.3Cr 114.56Cr 103.74Cr 195.65Cr 13TCr 197.23Cr 1.37TCr 534.62Cr 6.77TCr 516.8Cr 505.71Cr 22TCr
Net income 15Cr 13Cr 12Cr 11Cr 21Cr 1.4TCr 21Cr 145.2Cr 56Cr 714.67Cr 55Cr 53Cr 2.3TCr 22Cr 19Cr 18Cr 16Cr 31Cr 2.1TCr 31Cr 218.07Cr 85Cr 1.07TCr 82Cr 80Cr 3.45TCr
Net Debt -187.11Cr -166.2Cr -155.68Cr -140.98Cr -265.87Cr -18TCr -268.02Cr -1.87TCr -726.51Cr -9.2TCr -702.3Cr -687.22Cr -30TCr -214.54Cr -190.57Cr -178.5Cr -161.64Cr -304.84Cr -21TCr -307.31Cr -2.14TCr -833.01Cr -11TCr -805.25Cr -787.96Cr -34TCr
Projected Income Statement - Annual - PTC Therapeutics, Inc.
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. It is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD), a rare life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its ST-920, or isaralgagene civaparvovec, is a one-time administered AAV gene therapy product candidate for the treatment of Fabry disease.
Employees
991
Date Price Change Volume
06/26/06 $63.70 +0.08% 12,52,442
05/26/05 $63.65 +0.30% 10,44,025
02/26/02 $63.46 -1.04% 8,95,554
01/26/01 $64.13 -1.00% 11,97,752
30/26/30 $64.78 -0.28% 10,43,320
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Ratings Surperformance© - PTC Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
63.70USD
Average target price
101.79USD
Spread / Average Target
+59.79%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - PTC Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. PTCT Stock